Aurora Investment Managers LLC. Makes New $2.68 Million Investment in Pfizer Inc. $PFE

Aurora Investment Managers LLC. acquired a new stake in Pfizer Inc. (NYSE:PFE) in the 4th quarter, according to its most recent disclosure with the SEC. The fund acquired 107,664 shares of the biopharmaceutical company’s stock, valued at approximately $2,681,000. Pfizer makes up about 1.5% of Aurora Investment Managers LLC.’s portfolio, making the stock its 27th largest holding.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Fiduciary Alliance LLC raised its stake in shares of Pfizer by 46.4% during the third quarter. Fiduciary Alliance LLC now owns 145,263 shares of the biopharmaceutical company’s stock valued at $3,701,000 after acquiring an additional 46,043 shares during the last quarter. Y Intercept Hong Kong Ltd acquired a new stake in shares of Pfizer in the 3rd quarter worth about $3,019,000. Money Concepts Capital Corp lifted its holdings in shares of Pfizer by 29.9% in the third quarter. Money Concepts Capital Corp now owns 248,251 shares of the biopharmaceutical company’s stock valued at $6,325,000 after purchasing an additional 57,188 shares in the last quarter. Vista Investment Partners LLC lifted its stake in Pfizer by 236.1% during the 3rd quarter. Vista Investment Partners LLC now owns 69,613 shares of the biopharmaceutical company’s stock valued at $1,774,000 after acquiring an additional 48,900 shares in the last quarter. Finally, Kepler Cheuvreux Suisse SA bought a new position in shares of Pfizer during the third quarter valued at about $16,613,000. Institutional investors own 68.36% of the company’s stock.

Key Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Topline Phase 3 win for TALZENNA (talazoparib) + XTANDI: the TALAPRO-3 study met its primary endpoint, showing a significant delay in radiographic progression-free survival in HRR‑mutated metastatic castration‑sensitive prostate cancer — a meaningful commercial and clinical win for Pfizer’s oncology franchise. TALZENNA Plus XTANDI Significantly Improves Radiographic Progression-Free Survival in Metastatic Prostate Cancer
• Positive Sentiment: Additional oncology progress: a Phase II study of atirmociclib in second‑line metastatic breast cancer hit its primary endpoint, supporting pipeline diversification beyond vaccines and COVID-era revenues. PFE’s Atirmociclib 2L Breast Cancer Study Hits Goal, Aid Pipeline Push
• Positive Sentiment: Analyst interest/upgrade flow: recent analyst upgrades and a bullish HSBC forecast have lent buy‑side support and renewed attention to Pfizer’s valuation and upside potential. Pfizer (NYSE:PFE) Stock Price Up 3.2% Following Analyst Upgrade
• Neutral Sentiment: Pfizer-linked investment activity: Earendil Labs closed a $787M financing that included participation from a biotech development fund associated with Pfizer — a sign of strategic R&D/venture exposure but not an immediate earnings driver. Earendil Labs Announces $787 Million in Financing to Scale AI-Driven Biologics Discovery and Development
• Neutral Sentiment: Market commentary and valuation focus: several recent pieces reassess Pfizer’s valuation and compare it to peers (e.g., Moderna), keeping the stock in investors’ screens but creating mixed sentiment around near‑term upside. Reassessing Pfizer (PFE) Valuation As Shares Trade Around Recent Levels
• Negative Sentiment: Unsolicited mini‑tender offer: Tutanota LLC filed a conditional mini‑tender to buy up to 1M Pfizer shares at $32 — Pfizer has advised shareholders to reject it. The offer is unlikely to be material but can create short‑term trading noise. Pfizer Recommends Shareholders Reject the Mini-Tender Offer by Tutanota LLC

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the company. Citigroup initiated coverage on Pfizer in a report on Tuesday, December 2nd. They issued a “neutral” rating and a $26.00 target price for the company. Guggenheim reissued a “buy” rating on shares of Pfizer in a research report on Wednesday, December 17th. Wolfe Research set a $24.00 price objective on Pfizer and gave the company an “underperform” rating in a research note on Wednesday, December 17th. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $27.00 target price on shares of Pfizer in a research report on Wednesday, February 4th. Finally, Weiss Ratings reiterated a “hold (c-)” rating on shares of Pfizer in a research note on Thursday, January 22nd. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, thirteen have given a Hold rating and three have given a Sell rating to the company. Based on data from MarketBeat, Pfizer has a consensus rating of “Hold” and an average price target of $28.14.

Pfizer Stock Down 1.6%

Pfizer stock opened at $26.98 on Monday. The firm has a 50 day simple moving average of $26.68 and a 200 day simple moving average of $25.61. The company has a current ratio of 1.16, a quick ratio of 0.87 and a debt-to-equity ratio of 0.71. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $27.94. The firm has a market capitalization of $153.41 billion, a price-to-earnings ratio of 19.84 and a beta of 0.47.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 EPS for the quarter, topping analysts’ consensus estimates of $0.57 by $0.09. The firm had revenue of $17.56 billion during the quarter, compared to analyst estimates of $16.93 billion. Pfizer had a return on equity of 20.48% and a net margin of 12.42%.The business’s revenue for the quarter was down 1.2% on a year-over-year basis. During the same period last year, the company earned $0.63 earnings per share. On average, analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.